The main drivers of growth in graft versus host disease over the 2013-2023 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.

Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. J&J’s Remicade, has gained a significant patent share of the aGVHD patient group, as it is one of the few drugs that are efficient in GVHD with GI involvement. Gaining more and more ground in the treatment management of cGVHD is Roche’s Rituxan that GlobalData estimates will be one of the bestselling biologics in GVHD in the US by 2023.

Browse full report with TOC @

Despite the vast array of available off-label therapies for the treatment and/or prevention of GVHD, very few of these therapies have been tested in large randomized trials. This results in vague treatment recommendations and many patients being enrolled in institutional clinical trials. The only available standard of care is intravenous methylprednisolone that fails to produce a complete response in more than 50% of treated patients. Steroid-refractory subgroups face low prognosis with deteriorating quality of life. Second and third life treatments can vary from country to country but also between different medical institutions in the same country.

The GVHD market was valued at $297.0m across the 6MM in 2013, and is expected to increase to $544.4m in 2023, at a Compound Annual Growth Rate (CAGR) of 12.84%.


Key Questions Answered

– How will the GVHD market landscape change within the 2013-2023 forecast period in the 6MM?
– What are the most promising late-stage pipeline drugs in GVHD?
– How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
– What are the unmet needs in GVHD treatment management?
– What needs to change in the GVHD R&D and treatment guidelines settings?

View all reports of this category @

Key Findings

– High uptake of off-label biologics (Rituxan, Lemtrada, Remicade and Thymoglobuline)
– No national guidelines are in place
– GVHD remains a field of highly unattained unmet need
– No consensus over clinical trial endpoints
– Regulatory T cells (Tregs) are the focus of the early stage pipeline
– Huge opportunity exists in the chronic patient segment of GVHD
– Institutionally funded studies are the core of GVHD treatment management


– Overview of GVHD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
– Annualized GVHD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2023.
– Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the GVHD therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including TNF blockers, CD25a blockers, GVHD-specific therapies etc.
– Analysis of the current and future market competition in the US and five major EU GVHD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Blog URL:

About Acute Market Reports

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. Acute Market Reports provide online reports from over 100 best publishers and upgrade Acute Market Reports collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Acute Market Reports database consists of 200,000+ market research reports with detailed & minute market research.


Chris Paul

Office No 01, 1st Floor,

Aditi Mall, Baner, Pune,

MH, 411045 India

Phone (India): +91 7755981103

Toll Free (US/Canada): +1-855-455-8662


For More Information Click Here – Acute Market Reports